慢性腎臟病市場規模、佔有率和成長分析（按診斷、治療方法、給藥途徑、最終用戶和地區分類）－2025-2032年產業預測

預計到 2023 年，全球慢性腎臟病(CKD) 市場規模將達到 141 億美元，到 2024 年將達到 169.3 億美元，到 2032 年將達到 733 億美元，預測期（2025-2032 年）的複合年成長率為 20.1%。

由於糖尿病和高血壓盛行率不斷上升，全球慢性腎臟病（CKD）市場正經歷強勁成長，而糖尿病和高血壓正是CKD的主要誘發因素。隨著全球人口老化，腎功能的自然衰退進一步加劇了這個問題。患者和醫療保健提供者對CKD的認知不斷提高，推動了CKD的早期發現和診斷，進而維持了對治療藥物、介入策略和創新技術治療方法的高需求。人們對CKD認知的不斷提高以及對有效管理方案的迫切需求是市場的主要促進因素，確保了醫療保健領域在應對這一慢性疾病方面持續成長和拓展的機會。

全球慢性腎臟病市場促進因素

全球慢性腎臟病市場的主要驅動力是糖尿病和高血壓患者群體，這兩種疾病是導致腎功能障礙的兩大主要原因。隨著這些嚴重慢性疾病盛行率的上升，對治療方案的需求必然增加，這與慢性腎臟病發病率的上升密切相關。不斷成長的患者群體凸顯了有效治療性介入和管理策略的緊迫性，並強調了在更廣泛的慢性病管理框架下，需要能夠應對腎臟健康複雜性的醫療保健解決方案。因此，這為市場創新和發展提供了巨大的機會。

限制全球慢性腎臟病市場的因素

晚期慢性腎臟病的治療面臨巨大的經濟挑戰，因為透析和腎臟移植等治療費用高昂。這種經濟負擔不僅給病人帶來沉重的負擔，尤其是在優質醫療保險覆蓋範圍有限的地區，也影響著國家醫療體系的財政資源。高昂的治療費用會阻礙患者獲得所需的醫療服務，導致患者治療效果不均，並給醫療預算帶來額外的壓力。因此，解決這些經濟難題對於改善慢性腎臟病病患者的治療效果，確保所有患者都能公平地獲得醫療服務至關重要。

全球慢性腎臟病市場趨勢

全球慢性腎臟病市場正經歷著向早期診斷和積極干預策略的重大轉變。這一發展趨勢強調早期發現和管理的重要性，而非僅僅關注終末期治療，尤其是在高危險群中。世界各地的醫療保健系統日益重視預防措施，推動篩檢技術和診斷工具的創新。這一趨勢旨在早期識別慢性腎臟病，最終促進能夠有效延緩疾病進展的新型療法的研發。因此，預計該市場將迎來顯著成長，體現了腎臟健康管理綜合辦法。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2024）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

慢性腎臟病市場規模（按診斷和複合年成長率分類）（2025-2032 年）

• 市場概覽
• 血液檢查
  • 血清肌酸酐檢測
  • 腎絲球過濾率（GFR）測試
  • 血中尿素氮（BUN）檢測
  • 電解質測試
• 尿液檢查
  • 尿液檢查
  • 24小時尿液收集
  • 尿蛋白檢測
  • 尿液白蛋白肌酸酐比值（ACR）
• 影像檢查
  • 超音波
  • 電腦斷層掃描
  • MRI
  • X光
• 切片檢查
  • 經皮皮腎切片檢查
  • 開放式切片檢查
  • 腹腔鏡切片檢查

慢性腎臟病市場規模（依療法分類）及複合年成長率（2025-2032 年）

• 市場概覽
• 藥物
• 透析
• 腎臟移植
• ACE抑制劑
• 血液檢查
• 其他治療方法

慢性腎臟病市場規模（依給藥途徑及複合年成長率分類）（2025-2032 年）

• 市場概覽
• 口服
• 靜脈注射
• 皮下注射

慢性腎臟病市場規模（依最終用戶分類）及複合年成長率（2025-2032 年）

• 市場概覽
• 醫院和診所
• 門診手術中心（ASC）
• 透析中心
• 其他最終用戶

慢性腎臟病市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2024 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2024 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2022-2024年營收年比比較

主要企業簡介

• AstraZeneca（United Kingdom）
• Amgen Inc.（United States）
• Bayer AG（Germany）
• Fresenius Medical Care（Germany）
• DaVita Inc.（United States）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Baxter International Inc.（United States）
• Novartis AG（Switzerland）
• Johnson & Johnson（United States）
• Pfizer Inc.（United States）
• GlaxoSmithKline plc（GSK）（United Kingdom）
• AbbVie Inc.（United States）
• Boehringer Ingelheim International GmbH（Germany）
• Travere Therapeutics（United States）
• Vera Therapeutics（United States）
• ProKidney（United States）
• Akebia Therapeutics（United States）
• Calliditas Therapeutics AB（Sweden）
• Becton, Dickinson and Company（BD）（United States）
• Renalytix Plc（United Kingdom）

結論與建議

Global Chronic Kidney Disease Market size was valued at USD 14.1 billion in 2023 and is poised to grow from USD 16.93 billion in 2024 to USD 73.3 billion by 2032, growing at a CAGR of 20.1% during the forecast period (2025-2032).

The global chronic kidney disease (CKD) market is experiencing robust growth due to the increasing prevalence of diabetes and hypertension, which are key contributors to CKD. As the global population ages, the natural decline in kidney function exacerbates this issue. Growing awareness among patients and healthcare providers is fostering early identification and diagnosis of CKD, which in turn sustains high demand for therapeutic drugs, intervention strategies, and innovative technological treatments. This heightened recognition of CKD and the urgency for effective management solutions are key market drivers, ensuring continuous growth and expansion opportunities within the healthcare sector addressing this chronic condition.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Chronic Kidney Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Chronic Kidney Disease Market Segments Analysis

Global Chronic Kidney Disease Market is segmented by Diagnosis, Treatment, Route of Administration, End User and region. Based on Diagnosis, the market is segmented into Blood Test, Urine Test, Imaging Test and Kidney Biopsy. Based on Treatment, the market is segmented into Drugs, Dialysis, Kidney Transplant, ACE Inhibitors, Blood Test and Other Treatments. Based on Route of Administration, the market is segmented into Oral, Intravenous and Subcutaneous. Based on End User, the market is segmented into Hospital and Clinics, Ambulatory Surgery Centers (ASCs), Dialysis Centers and Other End-Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Chronic Kidney Disease Market

The global market for chronic kidney disease is primarily driven by individuals suffering from diabetes and hypertension, the two leading contributors to kidney impairment. As the prevalence of these significant chronic conditions intensifies, the demand for treatment options will inevitably rise, correlating with an increased incidence of chronic kidney disease. This growing patient population highlights the urgent need for effective therapeutic interventions and management strategies, emphasizing the urgency for healthcare solutions that address the complexities of kidney health within the broader framework of chronic disease management. Consequently, this presents substantial opportunities for innovation and development within the market.

Restraints in the Global Chronic Kidney Disease Market

The management of advanced chronic kidney disease presents substantial financial challenges, as treatments such as dialysis and kidney transplants entail considerable expenses. This financial strain not only translates to a heavy burden for patients, particularly in regions with limited access to quality health insurance, but it also impacts the fiscal resources of national healthcare systems. The high costs associated with care can create barriers to accessing necessary treatments, leading to disparities in patient outcomes and placing additional stress on healthcare budgets. As a result, addressing these economic constraints is crucial for improving care and ensuring equitable access for all patients facing chronic kidney disease.

Market Trends of the Global Chronic Kidney Disease Market

The global chronic kidney disease market is witnessing a significant shift towards early diagnosis and proactive intervention strategies. This evolving trend emphasizes the importance of early detection and management, particularly for at-risk populations, rather than solely focusing on late-stage treatment. Healthcare systems worldwide are increasingly prioritizing preventive measures, fostering innovations in screening technologies and diagnostic tools. This movement aims to identify chronic kidney disease in its initial stages, ultimately driving the development of novel therapeutic agents designed to slow disease progression effectively. As a result, the market is poised for substantial growth, reflecting a holistic approach to kidney health management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Chronic Kidney Disease Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Blood Test
  • Serum Creatinine Test
  • Glomerular Filtration Rate (GFR) Test
  • Blood Urea Nitrogen (BUN) Test
  • Electrolyte Tests
• Urine Test
  • Urinalysis
  • 24-hour Urine Collection
  • Urine Protein Test
  • Urine Albumin-To-Creatinine Ratio (ACR)
• Imaging Test
  • Ultrasound
  • CT Scan
  • MRI
  • X-ray
• Kidney Biopsy
  • Percutaneous Kidney Biopsy
  • Open Kidney Biopsy
  • Laparoscopic Kidney Biopsy

Global Chronic Kidney Disease Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Drugs
• Dialysis
• Kidney Transplant
• ACE Inhibitors
• Blood Test
• Other Treatments

Global Chronic Kidney Disease Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intravenous
• Subcutaneous

Global Chronic Kidney Disease Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospital and Clinics
• Ambulatory Surgery Centers (ASCs)
• Dialysis Centers
• Other End-Users

Global Chronic Kidney Disease Market Size & CAGR (2025-2032)

• North America (Diagnosis, Treatment, Route of Administration, End User)
  • US
  • Canada
• Europe (Diagnosis, Treatment, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Medical Care (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DaVita Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Travere Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vera Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ProKidney (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akebia Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Calliditas Therapeutics AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Renalytix Plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations